SKI306X inhibition of glycosaminoglycan degradation in human cartilage involves down-regulation of cytokine-induced catabolic genes.
10.3904/kjim.2014.29.5.647
- Author:
Choong Hyeok CHOI
1
;
Tae Hwan KIM
;
Yoon Kyoung SUNG
;
Chan Bum CHOI
;
Young In NA
;
Hunseung YOO
;
Jae Bum JUN
Author Information
1. Department of Surgery for Rheumatism, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Aggrecanase;
Cartilage;
Matrix metalloproteinase;
Osteoarthritis;
SKI306X
- MeSH:
ADAM Proteins/antagonists & inhibitors;
Cartilage, Articular/*drug effects/*metabolism;
Cells, Cultured;
Chondrocytes/drug effects/metabolism;
Down-Regulation/drug effects;
Drugs, Chinese Herbal/*pharmacology;
Glycosaminoglycans/*metabolism;
Humans;
Interleukin-1beta/metabolism;
Matrix Metalloproteinase 13/metabolism;
Matrix Metalloproteinase Inhibitors/pharmacology;
Oncostatin M/metabolism;
Osteoarthritis, Knee/drug therapy/genetics/metabolism;
Procollagen N-Endopeptidase/antagonists & inhibitors
- From:The Korean Journal of Internal Medicine
2014;29(5):647-655
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: SKI306X, a mixed extract of three herbs, Clematis mandshurica (CM), Prunella vulgaris (PV), and Trichosanthes kirilowii (TK), is chondroprotective in animal models of osteoarthritis (OA). The objectives of this study were to investigate its effect on interleukin (IL)-1beta-induced degradation of glycosaminoglycan (GAG) and the basis of its action in human OA cartilage, as well as to screen for the presence of inhibitors of matrix metalloproteinase (MMP)-13 and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS)-4 in SKI306X and its component herbs, as well as in fractions from SKI306X. METHODS: Human OA chondrocytes and cartilage explants were obtained during total knee replacements and incubated with IL-1beta +/- oncostatin M with or without SKI306X or its component herb extracts. GAG degradation was assayed in cartilage explants using a commercial kit. Expression of genes involved in cartilage destruction was measured by real-time polymerase chain reaction using chondrocyte RNA. SKI306X was fractionated by preparative liquid chromatography to test for the presence of inhibitors of MMP-13 and ADAMTS-4. RESULTS: SKI306X and PV inhibited IL-1beta-induced GAG release from cartilage explants, and SKI306X, CM, PV, and TK inhibited IL-1beta-induced MMP gene expression. Unexpectedly, SKI306X greatly stimulated IL-1beta + oncostatin M-induced ADAMTS-4 gene expression, probably due to its TK component. Some fractions of SKI306X also inhibited ADAMTS-4 activity. CONCLUSIONS: SKI306X and its herbal components inhibit GAG degradation and catabolic gene expression in human OA chondrocytes and cartilage explants. SKI306X likely also contains one or more ADAMTS-4 inhibitor.
